GLP1R and diabetes mellitus: It is worth to mention, that the document published recently in order to address enormous progress in the field of diabetes and DKD stemming from the results of landmark GLP1 receptor agonist and SGLT2 inhibitor trials, namely the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease does not mention the role of a low-phosphate diet as nephroprotective strategy.